Safety and efficacy of lorlatinib against ALK-driven refractory or relapsed neuroblastoma.

ABSTRACT: We spotlight the promising preliminary findings reported by Goldsmith et al. of a phase 1 first-in-child study showcasing the safety and efficacy of lorlatinib against treatment-refractory or relapsed ALK-driven neuroblastoma.¹.

SUBMITTER: Suk Y 

PROVIDER: S-EPMC10313925 | biostudies-literature | 2023 Jun

REPOSITORIES: biostudies-literature